Nurexone Biologic Inc (NRX.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 39 | 18 | 13 | 15 | 3 |
| Accounts receivable | 1 | 99 | -3 | -185 | -79 |
| Other Working Capital | -561 | 98 | 122 | -582 | -99 |
| Other Operating Activity | -1,214 | -1,033 | -1,002 | -713 | -458 |
| Operating Cash Flow | $-1,735 | $-818 | $-870 | $-1,465 | $-633 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -46 | -301 | -61 | -241 | -67 |
| Other Investing Activity | 1 | 0 | -10 | 0 | 23 |
| Investing Cash Flow | $-45 | $-301 | $-71 | $-241 | $-44 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -7 | -8 | -7 | -8 | -8 |
| Common Stock Issued | 1,379 | 764 | 0 | 566 | 3 |
| Other Financing Activity | -1,195 | 503 | 51 | 3,840 | 95 |
| Financing Cash Flow | $177 | $1,259 | $44 | $4,398 | $90 |
| Exchange Rate Effect | -220 | -2 | 27 | 22 | -15 |
| Beginning Cash Position | 2,523 | 2,385 | 3,255 | 541 | 1,143 |
| End Cash Position | 700 | 2,523 | 2,385 | 3,255 | 541 |
| Net Cash Flow | $-1,603 | $140 | $-897 | $2,692 | $-587 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,735 | -818 | -870 | -1,465 | -633 |
| Capital Expenditure | -46 | -301 | -61 | -241 | -67 |
| Free Cash Flow | -1,781 | -1,119 | -931 | -1,706 | -700 |